Maven Securities’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Maven Securities’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-67,856	Closed	-$82K	–	1412
2020 Q4	$82K	Sell	67,856 -1,800	-3%	-$3.83K	0.01%	535
2020 Q3	$143K	Hold	69,656	–	–	0.01%	570
2020 Q2	$243K	Sell	69,656 -25,000	-26%	-$90.2K	0.02%	465
2020 Q1	$360K	Hold	94,656	–	–	0.04%	206
2019 Q4	$291K	Buy	+94,656	New	+$246K	0.03%	302

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Maven Securities's BMY.RT Position: Q1 2021 in Review

Maven Securities sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 67,856 shares — an estimated $82K sold.

Maven Securities first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $360K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Maven Securities reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Maven Securities sold 67,856 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $82K.
Maven Securities first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Maven Securities's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $360K in Q1 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Maven Securities's 13F filing for Q1 2021, filed 17 May 2021.